CSIMarket
 


Johnson and Johnson  (JNJ)
Other Ticker:  
 
 

JNJ's Capital Expenditures Growth by Quarter and Year

Johnson And Johnson's Capital Expenditures results by quarter and year




JNJ Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter January - 1,323.00 1,260.00 1,318.00
III Quarter October - 737.00 745.00 819.00
II Quarter July - 662.00 837.00 875.00
I Quarter April 677.00 625.00 656.00 658.00
FY   677.00 3,347.00 3,498.00 3,670.00



JNJ Capital Expenditures first quarter 2021 Y/Y Growth Comment
Johnson and Johnson reported Capital Expenditures growth of 8.32% year on year in the first quarter, to $ 677.00 millions, this is lower than Johnson And Johnson's recent average Capital Expenditures increase of 18.07%.

Looking into first quarter results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Capital Expenditures growth. While Johnson And Johnson' s Capital Expenditures increase of 8.32% ranks overall at the positon no. 229 in the first quarter.




JNJ Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter January - 5 % -4.4 % 6.29 %
III Quarter October - -1.07 % -9.04 % 3.67 %
II Quarter July - -20.91 % -4.34 % 27 %
I Quarter April 8.32 % -4.73 % -0.3 % 17.5 %
FY   - -4.32 % -4.69 % 11.92 %

Financial Statements
Johnson And Johnson's first quarter 2021 Capital Expenditures $ 677.00 millions JNJ's Income Statement
Johnson And Johnson's first quarter 2020 Capital Expenditures $ 625.00 millions Quarterly JNJ's Income Statement
New: More JNJ's historic Capital Expenditures Growth >>


JNJ Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter January - 79.51 % 69.13 % 60.93 %
III Quarter October - 11.33 % -10.99 % -6.4 %
II Quarter July - 5.92 % 27.59 % 32.98 %
I Quarter April -48.83 % -50.4 % -50.23 % -46.94 %
FY (Year on Year)   - -4.32 % -4.69 % 11.92 %




Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #28
Overall #229

Capital Expenditures Y/Y Growth Statistics
High Average Low
694.28 % 18.07 % -7.8 %
(Dec. 30. 2009)   (Jan 01 2017)
Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #28
Overall #229
Capital Expenditures Y/Y Growth Statistics
High Average Low
694.28 % 18.07 % -7.8 %
(Dec. 30. 2009)   (Jan 01 2017)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Johnson And Johnson's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.4 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Johnson And Johnson realized fall in Capital Expenditures from the previous quarter by -48.83% to $ 677.00 millions, from $ 1,323.00 millions declared in the previous reporting period.

This is not huge problem, as Capital Expenditures frequently gravitate to slow in this quarter.

Within Major Pharmaceutical Preparations industry 80 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 1621.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #81
Healthcare Sector #243
Overall #1621
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #81
Healthcare Sector #243
Overall #1621
Capital Expenditures Q/Q Growth Statistics
High Average Low
174.48 % 14.4 % -100 %
(Dec. 30. 2011)  


JNJ's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Johnson And Johnson realized fall in Capital Expenditures from the forth quarter by -48.83% to $ 677.00 millions, from $ 1,323.00 millions achived in the previous quarter.

As we look into current shortcoming at the I. Quarter, we must take into consideration, that commonly I. Quarter 2021 results emerge weaker then in the forth quarter

Within Major Pharmaceutical Preparations industry 80 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Johnson And Johnson's Capital Expenditures growth quarter on quarter, overall rank is 1621.


Johnson And Johnson's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Apr 04 2021)
12 Months Ending
(Jan 03 2021)
12 Months Ending
(Sep 27 2020)
12 Months Ending
(Jun 28 2020)
12 Months Ending
(Mar 29 2020)
Cumulative Capital Expenditures 12 Months Ending $ 3,399.00 $ 3,347.00 $ 3,284.00 $ 3,292.00 $ 3,467.00
Y / Y Capital Expenditures Growth (TTM) -1.96 % -4.32 % -7.65 % -9.31 % -5.48 %
Year on Year Capital Expenditures Growth Overall Ranking # 951 # 1268 # 1387 # 1521 # 1653
Seqeuential Capital Expenditures Change (TTM) 1.55 % 1.92 % -0.24 % -5.05 % -0.89 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 969 # 1157 # 1236 # 1606 # 1611




Cumulative Capital Expenditures growth Comment
Johnson And Johnson showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jan 03 2021. If the fiscal year would end in Apr 04 2021, Johnson And Johnson's annual Capital Expenditures decline would be -1.96% year on year to $3,399 millions.

In the Healthcare sector 206 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 951, from total ranking in previous quarter at 1268.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
18.07 %
-7.8 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 207
Overall # 951

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
19.85 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 205
S&P 500 # 969
Cumulative Capital Expenditures growth Comment
Johnson And Johnson showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jan 03 2021. If the fiscal year would end in Apr 04 2021, Johnson And Johnson's annual Capital Expenditures fall would be -1.96% year on year to $3,399 millions.

In the Healthcare sector 206 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 951, from total ranking in previous quarter at 1268.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
694.28 %
18.07 %
-7.8 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 207
Overall # 951

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
661.98 %
19.85 %
-13.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 205
S&P 500 # 969




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
JNJ's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for JNJ's Competitors
Capital Expenditures Growth for Johnson And Johnson's Suppliers
Capital Expenditures Growth for JNJ's Customers

You may also want to know
JNJ's Annual Growth Rates JNJ's Profitability Ratios JNJ's Asset Turnover Ratio JNJ's Dividend Growth
JNJ's Roe JNJ's Valuation Ratios JNJ's Financial Strength Ratios JNJ's Dividend Payout Ratio
JNJ's Roa JNJ's Inventory Turnover Ratio JNJ's Growth Rates JNJ's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Apr 04 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Apr 04 2021


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MTRX's Profile

Stock Price

MTRX's Financials

Business Description

Fundamentals

Charts & Quotes

MTRX's News

Suppliers

MTRX's Competitors

Customers & Markets

Economic Indicators

MTRX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071